Arcellx shareholders set to receive USD 115 per share in Gilead deal
Reuters03-17 23:27
Arcellx shareholders set to receive USD 115 per share in <a href="https://laohu8.com/S/GILD">Gilead</a> deal
Arcellx agreed to be sold to Gilead Sciences under terms that include USD 115 per share in cash. Arcellx shareholders are also expected to receive a contingent value right of USD 5 per share tied to certain milestone achievements. The tender offer for the transaction is set to expire on April 2, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcellx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603171126PRIMZONEFULLFEED9673556) on March 17, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments